Alnylam Execs在收入亏损后出售股票,尽管股票随着收入强劲增长而上升。 Alnylam execs sold shares after earnings miss, though stock rose on strong revenue growth.

2026年2月13日,Alnylam制药公司执行董事Yvonne Greenstreet出售6 958股,每股310.08美元,净额216万美元,Tolga Tanguler出售1 959股,607 447美元。 On February 13, 2026, Alnylam Pharmaceuticals executive Yvonne Greenstreet sold 6,958 shares at $310.08 each, netting $2.16 million, while executive Tolga Tanguler sold 1,959 shares for $607,447. 销售是继该公司2月12日的收入报告之后进行的,报告显示EPS为82美元,收入为11亿美元,没有预期。 The sales followed the company’s February 12 earnings report showing $0.82 EPS and $1.10 billion in revenue, missing expectations. 尽管年收入增加了84.9%,但Alnylam的股票在2月18日上涨了18.21美元,增至332.61美元,分析师维持“Moderate Buy”共识,目标价格为477.96.6美元。 Despite an 84.9% year-over-year revenue increase, Alnylam’s stock rose $18.21 to $332.61 on February 18, with analysts maintaining a “Moderate Buy” consensus and a target price of $477.96.